Review articleAGXT2: An unnegligible aminotransferase in cardiovascular and urinary systems

- Clarification of possible pathogenesis in CVDs and renal diseases is very challenging and important.
- Dimethylarginines are associated with renal function and CVDs/cardiovascular events.
- AGXT2 may contribute to the progression of CVDs/renal diseases owing to its ability in dimethylarginines metabolism.
- Recent work discusses potential impact of AGXT2 on CVDs/renal diseases.

Cardiovascular diseases (CVDs) and renal impairment interact in a complex and interdependent manner, which makes clarification of possible pathogenesis between CVDs and renal diseases very challenging and important. There is increasing evidence showing that both asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) play a crucial role in the development of CVDs as well as in the prediction of cardiovascular events. Also, the plasma levels of ADMA and SDMA were reported to be significantly associated with renal function. Alanine-glyoxylate aminotransferase 2 (AGXT2) is reported to be involved in ADMA and SDMA metabolism, thus deficiency in the expression or activity of AGXT2 may play a part in the progression of cardiovascular or renal diseases through affecting ADMA/SDMA levels. Here, we focused our attention on AGXT2 and discussed its potential impact on CVDs and renal diseases. Meanwhile, the review also summarized the functions and recent advances of AGXT2, as well as the clinical association studies of AGXT2 in cardiovascular and urinary systems, which might arouse the interest of researchers in these fields.